NGEN NervGen Pharma Corp.

NSD
$1.74

NervGen Pharma Corp. (NGEN) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.0% since its last earnings release on August 13, 2026.

NervGen Pharma Missed Consensus Estimates
Thursday, August 13, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 7:15 AM ET
Earnings Whisper
-
vs ($0.09)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About NervGen Pharma Corp.

Nanogen, Inc. integrates advanced microelectronics and molecular biology into a core technology platform with broad and diverse commercial applications in the fields of genomics and biomedical research, medical diagnostics, drug discovery, forensics, agriculture, environmental testing and potentially the electronics and telecommunications industries.

Sector

Healthcare

Industry

Biotechnology